Theravance Biopharma, Inc.
TBPH
$18.43
-$1.18-6.02%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -23.69% | 70.23% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -23.69% | 70.23% | |||
| Cost of Revenue | -22.67% | -8.40% | |||
| Gross Profit | -24.37% | 299.01% | |||
| SG&A Expenses | -0.53% | 0.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.56% | -3.02% | |||
| Operating Income | -136.88% | 81.12% | |||
| Income Before Tax | -103.95% | 617.80% | |||
| Income Tax Expenses | -135.40% | 3,386.40% | |||
| Earnings from Continuing Operations | -93.41% | 503.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -93.41% | 503.82% | |||
| EBIT | -136.88% | 81.12% | |||
| EBITDA | -161.23% | 83.48% | |||
| EPS Basic | -93.45% | 500.00% | |||
| Normalized Basic EPS | -103.92% | 612.82% | |||
| EPS Diluted | -93.52% | 495.31% | |||
| Normalized Diluted EPS | -103.86% | 607.31% | |||
| Average Basic Shares Outstanding | 0.68% | 0.95% | |||
| Average Diluted Shares Outstanding | 2.33% | 2.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||